Challenges in the treatment of major depressive disorder with psychotic features

Schizophrenia Bulletin

Volumn 39, Issue 4, 2013, Pages 787-796

  Rothschild, Anthony J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

delusional depression; major depression with psychotic features; psychotic depression

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; NORTRIPTYLINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; SERTRALINE; TRIMIPRAMINE; VENLAFAXINE;

ARTICLE; BEHAVIOR THERAPY; BIPOLAR DISORDER; DEPRESSIVE PSYCHOSIS; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ELECTROCONVULSIVE THERAPY; FAMILY HISTORY; HAMILTON SCALE; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELATIVE; REMISSION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

EID: 84879375571     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt046     Document Type: Article

References (95)

1. Rothschild AJ (ed). Clinical Manual for the Diagnosis and Treatment of Psychotic Depression. Washington, DC: American Psychiatric Press; 2009.
2. Rothschild AJ, Winer J, Flint AJ, et al. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry. 2008; 69: 1293-1296.
3. Andreescu C, Mulsant BH, Peasley-Miklus C, et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007; 68: 194-200. (Pubitemid 46362639)
4. Paykel ES, Klerman GL, Prusoff BA. Treatment setting and clinical depression. Arch Gen Psychiatry. 1970; 22: 11-21.
5. Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry. 1977; 34: 197-204. (Pubitemid 8025017)
6. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992; 149: 733-745.
7. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? In: Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis WW, eds. DSM-IV Source Book Vol. 2. Washington, DC: American Psychiatric Press; 1996: 127-180.
8. American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
9. American Psychiatric Association Committee on Nomenclature. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.
10. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. Geneva: WHO; 1993.
11. Ostergaard SD, Rothschild AJ, Uggerby P, Munk-Jorgensen P, Bech P, Mors O. Considerations on the ICD-11 classification of psychotic depression. Psychother Psychosom. 2012; 81: 135-144.
12. Blazer D. Epidemiology of late-life depression. In: Schneider L, Reynolds C, Lebowitz B, Friedhoff A, eds. Diagnosis and Treatment of Depression in Late Life. Washington DC: American Psychiatric Press; 1994: 9-20.
13. Baldwin RC, Jolley DJ. The prognosis of depression in old age. Br J Psychiatry. 1986; 149: 574-583. (Pubitemid 17170928)
14. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry. 2002; 159: 1855-1861. (Pubitemid 35283250)
15. Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry. 1991; 48: 1075-1081.
16. Coryell W, Pfohl B, Zimmerman M. The clinical and neuroendocrine features of psychotic depression. J Nerv Ment Dis. 1984; 172: 521-528. (Pubitemid 14019613)
17. Gournellis R, Lykouras L. Psychotic (delusional) major depression in the elderly: a review. Current Psychiatry Reviews. 2006; 2: 235-244. (Pubitemid 44063173)
18. Akiskal HS, Walker P, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. J Affect Disord. 1983; 5: 115-128. (Pubitemid 13120405)
19. Aronson TA, Shukla S, Hoff A, Cook B. Proposed delusional depression subtypes: preliminary evidence from a retrospective study of phenomenology and treatment course. J Affect Disord. 1988; 14: 69-74. (Pubitemid 18016384)
20. Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry. 1982; 39: 549-555. (Pubitemid 12125546)
21. Othmer E, Desouza CM, Penick EC, et al. Indicators of mania in depressed outpatients: a retrospective analysis of data from the Kansas 1500 study. J Clin Psychiatry. 2007; 68: 47-51. (Pubitemid 46220123)
22. Prusoff BA, Weissman MM, Merikangas KR, Leckman JF, Harding PS. Psychiatric illness in relatives of probands with delusional depression. Psychopharmacol Bull. 1984; 20: 358-361. (Pubitemid 14090989)
23. Weissman MM, Prusoff BA, Merikangas KR. Is delusional depression related to bipolar disorder? Am J Psychiatry. 1984; 141: 892-893.
24. Weissman MM, Warner V, John K, et al. Delusional depression and bipolar spectrum: evidence for a possible association from a family study of children. Neuropsychopharmacology. 1988; 1: 257-264. (Pubitemid 19126144)
25. Blacker D, Faraone SV, Rosen AE, et al. Unipolar relatives in bipolar pedigrees: a search for elusive indicators of underlying bipolarity. Am J Med Genet. 1996; 67: 445-454.
26. Ostergaard SD, Waltoft BL, Mortensen PB, Mors O. Environmental and familial risk factors for psychotic and non-psychotic severe depression. J Affect Disord. 2012. doi: 10.1016/j.jad.2012.11.009.
27. Grunze H, Vieta E, Goodwin GM, et al. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010; 11: 81-109.
28. Leadholm AK, Rothschild AJ, Nolen WA, Bech P, Munk- Jorgensen P, Ostergaard SA. 2012. The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord. doi: 10.1016/j.jad.2012.07. 036.
29. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 3rd ed. 2010. http: //www.psychiatryonline.com/pracGuide/PracticePDFs/PG-Depression3rdEd.pdfS. Accessed March 13, 2013.
30. Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord. 2009; 117(Suppl 1): S44-S53.
31. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117(Suppl 1): S26-S43.
32. Suehs B, Argo TR, Bendele SD, Crismon ML, Trivedi MH, Kurian B. Texas Medication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms. Austin: Texas Department of State Health Services; 2008.
33. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002; 3: 5-43.
34. South African Society of Psychiatrists (SASOP). Major Depressive Disorder Guideline; 2008.
35. Royal Australian and New Zealand College of Psychiatrists (RANZCP). Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand J Psychiatry. 2004; 38: 389-407.
36. Danish Board of Health (DNBH). Guidelines for the Treatment of Unipolar Depression in Adults; 2007. www.sst.dk/publ/Publ2007/PLAN/SfR/SST-Dep.rapport. pdf. Accessed March 13, 2013.
37. National Institute for Health and Clinical Excellence (NICE). The treatment and management of depression in adults (updated edition) - National Clinical Practice 2010. http: //www.nice.org.uk/nicemedia/live/12329/45896/ 45896.pdf. Accessed March 13, 2013.
38. Dutch National Steering Committee Multidisciplinary Guideline Development Mental Health (DNSC). Multidisciplinary Guideline Depression; 2005.
39. Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews. 2005; CD004044, 005.
40. Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry. 2006; 188: 410-415.
41. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012; 73: 486-496.
42. Mulsant BH, Haskett RF, Prudic J, et al. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry. 1997; 154: 559-561. (Pubitemid 27147615)
43. Wijkstra J, Burger H, van den Broek WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand. 2010; 121: 190-200.
44. Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the Study Of Pharmacotherapy of Psychotic Depression (STOP-PD). Arch Gen Psychiatry. 2009; 66: 838-847.
45. Rothschild AJ, Williamson DJ, Tohen MF, et al. A doubleblind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004; 24: 365-373. (Pubitemid 38944133)
46. Kunzel HE, Ackl N, Hatzinger M, et al. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol - a double-blind multicenter trial. J Psychiatr Res. 2009; 43: 702-710.
47. Mulsant BH, Sweet RA, Rosen J, et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry. 2001; 62: 597-604. (Pubitemid 32848162)
48. Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 1990; 147: 1203-1208. (Pubitemid 20275376)
49. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985; 142: 430-436. (Pubitemid 15108205)
50. Simpson GM, El Sheshai A, Rady A, Kingsbury SJ, Fayek M. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. J Clin Psychiatry. 2003; 64: 959-965. (Pubitemid 37022765)
51. Bauer M, Dopfmer S. Lithium augmentation in treatmentresistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999; 19: 427-434. (Pubitemid 29451507)
52. Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry. 1983; 140: 318-322. (Pubitemid 13146695)
53. Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry. 1986; 143: 363-366. (Pubitemid 16034100)
54. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993; 54: 338-342. (Pubitemid 23322381)
55. Birkenhager TK, van den Broek WW, Wijkstra J, et al. Treatment of unipolar psychotic depression: an open study of lithium addition in refractory psychotic depression. J Clin Psychopharmacol. 2009; 29: 513-515.
56. Rothschild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am. 1996; 19: 237-252. (Pubitemid 26184101)
57. Kroessler D. Relative efficacy rates for therapies of delusional depression. Convuls Ther. 1985; 1: 173-182. (Pubitemid 15235383)
58. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord. 1992; 24: 17-24.
59. Olfson M, Marcus S, Sackeim HA, Thompson J, Pincus HA. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry. 1998; 155: 2-29.
60. Stoskopf C, Horn SD. Predicting length of stay for patients with psychoses. Health Serv Res. 1992; 26: 743-766.
61. Wilson KG, Kraitberg NJ, Brown JH, Bergman JN. Electroconvulsive therapy in the treatment of depression: the impact on length of stay. Compr Psychiatry. 1991; 32: 345-354.
62. Pande AC, Grunhaus LJ, Haskett RF, Greden JF. Electroconvulsive therapy in delusional and non-delusional depressive disorder. J Affect Disord. 1990; 19: 215-219. (Pubitemid 20209138)
63. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001; 17: 244-253. (Pubitemid 33131305)
64. Kho KH, Van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT. 2003; 19: 139-147. (Pubitemid 37087760)
65. Birkenhager TK, Pluijms EM, Lucius SA. ECT response in delusional versus non-delusional depressed inpatients. J Affect Disord. 2003; 74: 191-195. (Pubitemid 36428701)
66. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry. 2004; 55: 301-312. (Pubitemid 38117168)
67. Gaudiano BA, Nowlan K, Brown LA, Epstein-Lubow G, Miller IW. An open trial of a new acceptance-based behavioral treatment for major depression with psychotic features [published online ahead of print December 6, 2012]. Behav Modif.
68. Friedman M, Detweiler-Bedell J, Leventhal H, Horne R, Keitner G, Miller I. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. Clin Psychol Sci Prac. 2004; 11: 47-68. (Pubitemid 38735568)
69. Gould RA, Mueser KT, Bolton E, Mays V, Goff D. Cognitive therapy for psychosis in schizophrenia: an effect size analysis. Schizophren Res. 2001; 48: 335-342. (Pubitemid 32274327)
70. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: I. meta-analysis of family intervention and cognitive behavior therapy. Psychol Med. 2002; 32: 763-782. (Pubitemid 34823330)
71. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. J Nerv Ment Dis. 2001; 189: 278-287. (Pubitemid 32448649)
72. Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? Behav Res Ther. 2004; 42: 1377-1401. (Pubitemid 39410355)
73. Gaudiano BA, Beevers CG, Miller IW. Differential response to combined treatment in patients with psychotic versus nonpsychotic major depression. J Nerv Ment Dis. 2005; 193: 625-628. (Pubitemid 41298365)
74. Gaudiano BA, Miller IW, Herbert JD. The treatment of psychotic major depression: is there a role for adjunctive psychotherapy? Psychother Psychosom. 2007; 76: 271-277. (Pubitemid 47262745)
75. Jackson H, McGorry P, Edwards J, et al. Cognitively-oriented psychotherapy for early psychosis (COPE). Preliminary results. Br J Psychiatry Suppl. 1998; 172: 93-100. (Pubitemid 28258906)
76. Mueser KT, Rosenberg SD, Xie H, et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. J Consult Clin Psychol. 2008; 76: 259-271. (Pubitemid 351522260)
77. Trower P, Birchwood M, Meaden A, Byrne S, Nelson A, Ross K. Cognitive therapy for command hallucinations: randomised controlled trial. Br J Psychiatry. 2004; 184: 312-320. (Pubitemid 38491166)
78. Martell C, Addis M, Jacobson N. Depression in Context: Strategies for Guided Action. New York: Guilford; 2001.
79. Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy: The Process and Practice of Mindful Change, 2nd ed. New York: Guilford; 2012.
80. Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990; 10: 96-104. (Pubitemid 20137605)
81. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001; 285: 1299-1307. (Pubitemid 32216144)
82. Aronson TA, Shukla S, Hoff A. Continuation therapy after ECT for delusional depression: a naturalistic study of prophylactic treatments and relapse. Convuls Ther. 1987; 3: 251-259. (Pubitemid 18004987)
83. Murphy E. The prognosis of depression in old age. Br J Psychiatry. 1983; 142: 111-119. (Pubitemid 13180455)
84. Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC. Psychotic depression and mortality. Am J Psychiatry. 2003; 160: 574-576. (Pubitemid 41094270)
85. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry. 2003; 53: 1142-1145. (Pubitemid 36695090)
86. Meyers BS, Klimstra SA, Gabriele M, et al. Continuation treatment of delusional depression in older adults. Am J Geriatr Psychiatry. 2001; 9: 415-422. (Pubitemid 33015129)
87. Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry. 2003; 64: 390-396. (Pubitemid 36547280)
88. Flint AJ, Rifat SL. Two-year outcome of psychotic depression in late life. Am J Psychiatry. 1998; 155: 178-183. (Pubitemid 28074278)
89. Wijkstra J, Burger H, van den Broek WW, et al. Long-term response to successful acute pharmacological treatment of psychotic depression. J Affect Disord. 2010; 123: 238-242.
90. Deshauer D, Moher D, Fergusson D, Moher E, Sampson M, Grimshaw J. Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ. 2008; 178: 1293-1301. (Pubitemid 351678352)
91. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990; 47: 1093-1099.
92. Reynolds CF III, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006; 354: 1130-1138.
93. Flint AJ, Meyers BS, Rothschild AJ, et al. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II. BMC Psychiatry. 2013; 13: 38.
94. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993; 328: 839-846. (Pubitemid 23084338)
95. Birkenhager TK, van den Broek WW, Mulder PG, de Lely A. One-year outcome of psychotic depression after successful electroconvulsive therapy. J ECT. 2005; 21: 221-226. (Pubitemid 41772223)